Furthermore, the pharmacological blockade of PD-1/PDL-1 is mainly targeted towards PD-L1 expressing cancer cells, with less toxicity for patients in comparison to anti-CTLA-4 inhibitory antibody therapies, as has been reported in the case of advanced melanoma [26]. Here, CTLA4 is linked to cancer.